Kymera shareholders back board, pay and auditor
Kymera Therapeutics, Inc. reported the results of its Annual Meeting of Shareholders held on June 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Kymera Therapeutics, Inc. reported the results of its Annual Meeting of Shareholders held on June 24, 2026. Shareholders elected four Class III directors — Bruce Booth, Nello Mainolfi, John Maraganore and Elena Ridloff — each to serve three-year terms ending at the 2029 annual meeting.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 74,903,687 votes for and 2,462,732 against. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 79,043,801 votes for and minimal opposition.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Booth director election votes for: 71,962,459 votes
Mainolfi director election votes for: 73,411,316 votes
Say-on-pay votes for: 74,903,687 votes
+4 more
7 metrics
Booth director election votes for
71,962,459 votes
Votes for Bruce Booth as Class III director
Mainolfi director election votes for
73,411,316 votes
Votes for Nello Mainolfi as Class III director
Say-on-pay votes for
74,903,687 votes
Non-binding advisory approval of executive compensation
Say-on-pay votes against
2,462,732 votes
Non-binding advisory vote on executive compensation
Auditor ratification votes for
79,043,801 votes
Ratification of Ernst & Young LLP for fiscal year ending December 31, 2026
Auditor ratification votes against
38,128 votes
Ratification of Ernst & Young LLP
Broker non-votes on director elections
1,707,176 votes
Broker non-votes for each Class III director nominee
Key Terms
Annual Meeting of Shareholders, Class III directors, non-binding, advisory vote, named executive officers, +2 more
6 terms
Class III directors regulatory
"The shareholders of the Company elected Bruce Booth ... as Class III directors of the Company"
Class III directors are members of a company’s board assigned to one of several staggered term groups, so only that class faces election in a particular year while other classes stay in place. For investors this affects corporate control and takeover risk because staggered elections make it slower and harder for an outside group to replace a majority of directors quickly—think of it as a rotating schedule for board seats that provides continuity but can also entrench existing leadership.
non-binding, advisory vote regulatory
"The shareholders of the Company approved, on a non-binding, advisory basis, the compensation"
named executive officers financial
"The shareholders of the Company approved ... the compensation of the Company’s named executive officers"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
independent registered public accounting firm regulatory
"ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes regulatory
"The results of the shareholders’ vote ... include broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which directors were elected to Kymera Therapeutics’ board in 2026?
Shareholders elected Bruce Booth, D.Phil., Nello Mainolfi, Ph.D., John Maraganore, Ph.D., and Elena Ridloff, CFA as Class III directors. Each will serve a three-year term ending at the 2029 annual meeting, continuing the company’s existing board leadership structure.
Who is Kymera Therapeutics’ independent auditor for the year ending December 31, 2026?
Shareholders ratified Ernst & Young LLP as Kymera Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 79,043,801 votes for, 38,128 against, and 18,233 abstentions, with no broker non-votes reported.
Were there any other matters voted on at Kymera Therapeutics’ 2026 Annual Meeting?
No. Only three proposals were submitted to shareholders: election of four Class III directors, a non-binding advisory vote on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. No additional matters were presented or voted on.
What were the vote totals for Kymera Therapeutics’ director elections in 2026?
Votes for the Class III director nominees ranged from 71,962,459 to 73,411,316 in favor, with votes withheld ranging from 3,981,670 to 5,430,527. Each nominee also had 1,707,176 broker non-votes recorded, and all four were elected to serve three-year terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates